A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs OMP 313M32 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 09 May 2017 According to an OncoMed Pharmaceuticals media release, Johanna Bendell, M.D., Associate Director of the Drug Development Program at Sarah Cannon Research Institute is a lead investigator for the study.
- 04 May 2017 According to an OncoMed Pharmaceuticals media release, first patient has been dosed in the study.
- 26 Apr 2017 Status changed from not yet recruiting to recruiting.